Literature DB >> 19950708

[Factors influencing survival of patients with cancer of the pancreatic head after resection].

Chun-Tao Gao1, Hui-Kai Li, Qiang Li.   

Abstract

OBJECTIVE: The aim of this cohort study was to investigate the clinical outcome and prognostic factors in patients after resection for ductal adenocarcinoma of the pancreatic head.
METHODS: patients with pancreatic head cancer undergoing curative resection (R0) between 1997 and 2002 were included in this study. Univariate and multivariate analyses were performed to examine factors affecting clinical outcome and recurrence of the cancer.
RESULTS: Surgical procedures consisted of 58 (43.3%) extended pancreaticoduodenectomies (EPD), 47 (35.1%) pancreaticoduodenectomies (PD) and 29 (21.6%) pylorus-preserving pancreaticoduodenectomies (PPPD). The results showed that 81.3% (109/134) of patients had a recurrence during the study period, mainly retroperitoneal combined with distant metastasis (53.7%). The median postoperative survival time was 24.7 months. The 1-, 3- and 5-year overall survival rates for the study population were 67.1%, 38.5% and 17.6%, respectively. Univariate analysis showed that preoperative abdominal and/or back pain, tumor size > 2 cm, lymph node involvement and vascular invasion, and CA19-9 level were all significant predictors for poor survival. Multivariate analysis also showed that preoperative abdominal and/or back pain, tumor size > 2 cm, lymph node involvement and vascular invasion were all significant predictors for poor survival.
CONCLUSION: Our results suggest that preoperative abdominal and/or back pain, tumor size > 2 cm, lymph node involvement and vascular invasion are significant predictors for poor survival in patients with pancreatic head cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19950708

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  3 in total

1.  Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy.

Authors:  Deyali Chatterjee; Asif Rashid; Hua Wang; Matthew H Katz; Robert A Wolff; Gauri R Varadhachary; Jeffrey E Lee; Peter W Pisters; Henry F Gomez; James L Abbruzzese; Jason B Fleming; Huamin Wang
Journal:  Am J Surg Pathol       Date:  2012-04       Impact factor: 6.394

2.  Higher overall survival in metastatic pancreatic cancer: the impact of where and how treatment is delivered.

Authors:  Pedro Luiz Serrano Usón Junior; Monique Sedlmaier França; Heloisa Veasey Rodrigues; Antônio Luiz de Vasconcellos Macedo; Alberto Goldenberg; Oren Smaletz; Daniela Pezzutti Domingues Armentano; Sergio Daniel Simon; Rene Claudio Gansl
Journal:  Einstein (Sao Paulo)       Date:  2015-08-21

3.  Recurrence and Prognostic Value of Circulating Tumor Cells in Resectable Pancreatic Head Cancer: A Single Center Retrospective Study.

Authors:  Qiao Zhang; Feng Xia; Qiang Sun; Wenjing Cao; Ali Mo; Weiming He; Jiazhen Chen; Weiqiao Zhang; Weiqiang Chen
Journal:  Front Surg       Date:  2022-04-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.